Writing on precision oncology
Essays on the parts of precision oncology that are genuinely difficult — where the evidence is thin, where the reasoning is load-bearing, and where enthusiasm has outrun the data.
9 of 9
A Cancer Diagnosis Is Not a Treatment Plan
A diagnosis names a disease. A treatment plan answers a different set of questions, and the distance between the two is where most of the difficult work of oncology happens.
18 August 2026 · 7 MIN READ
Genomic Data Is Not the Destination
Sequencing a tumour is now straightforward. Knowing what the result means for this patient, in this clinical situation, is the part that has not become easy.
4 August 2026 · 8 MIN READ
Why More Mutations Do Not Necessarily Mean Better Decisions
Broader panels detect more alterations. Beyond a point, additional findings add interpretive burden faster than they add decision-relevant information.
21 July 2026 · 6 MIN READ
When Does ctDNA Actually Add Clinical Value?
Circulating tumour DNA is genuinely useful in specific, bounded situations. Being precise about which is more helpful than general enthusiasm.
7 July 2026 · 8 MIN READ
What Should AI Actually Do in Oncology?
The interesting question is not whether AI can produce plausible clinical text. It is which parts of oncological reasoning are genuinely bottlenecked, and whether machine assistance relieves them.
23 June 2026 · 9 MIN READ
From Molecular Report to Clinical Decision
The path from a molecular finding to a treatment decision passes through several inferential steps. Each has a strength, and naming them separately makes the whole chain assessable.
9 June 2026 · 7 MIN READ
Why Rare Cancer Patients Need a Different Information Architecture
Rare cancers are not simply under-researched common cancers. The evidence structure is different in kind, and the systems built for common disease do not degrade gracefully.
26 May 2026 · 7 MIN READ
Clinical Trial Matching: Finding the Relevant Trial, Not Just a Trial
Trial search rarely fails by returning nothing. It fails by returning a long undifferentiated list in which relevance and eligibility have not been assessed.
12 May 2026 · 6 MIN READ
The Future of Molecular Tumour Boards
Molecular tumour boards have become common. The question now is what makes one good, and whether its reasoning survives the meeting that produced it.
28 April 2026 · 7 MIN READ
No articles in that category yet.